Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Mast Cells and Sensory Nerves Contribute to Neurogenic Inflammation and Pruritus in Chronic Skin Inflammation

Hanna Siiskonen, Ilkka Harvima

Frontiers in Cellular Neuroscience · 2019 · Review · CC BY

doi:10.3389/fncel.2019.00422

Abstract

The intimate interaction between mast cells and sensory nerves can be illustrated by the wheal and surrounding flare in an urticarial reaction in human skin. This reaction is typically associated with an intense itch at the reaction site. Upon activation, cutaneous mast cells release powerful mediators, such as histamine, tryptase, cytokines, and growth factors that can directly stimulate corresponding receptors on itch-mediating sensory nerves. These include, e.g., H1- and H4-receptors, protease-activated receptor-2, IL-31 receptor, and the high-affinity receptor of nerve growth factor (TrkA). On the other hand, sensory nerves can release neuropeptides, including substance P and vasoactive intestinal peptide, that are able to stimulate mast cells to release mediators leading to potentiation of the reciprocal interaction, inflammation, and itch. Even though mast cells are well recognized for their role in allergic skin whealing and urticaria, increasing evidence supports the reciprocal function between mast cells and sensory nerves in neurogenic inflammation in chronic skin diseases, such as psoriasis and atopic dermatitis, which are often characterized by distressing itch, and exacerbated by psychological stress. Increased morphological contacts between mast cells and sensory nerves in the lesional skin in psoriasis and atopic dermatitis as well as experimental models in mice and rats support the essential role for mast cell-sensory nerve communication in consequent pruritus. Therefore, we summarize here the present literature pointing to a close association between mast cells and sensory nerves in pruritic skin diseases as well as review the essential supporting findings on pruritic models in mice and rats.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Itching is a very unpleasant sensation that may provoke scratching or the desire to scratch. Chronic itch has clinically been classified into 3 groups according to skin changes: (1) pruritus on primary diseased, inflamed skin; (2) pruritus on primary non-diseased, non-inflamed skin; and (3) pruritus with chronic secondary scratch lesions. Pruritus has also been categorized based on underlying diseases as following: (1) dermatological diseases; (2) systemic diseases including diseases of pregnancy and drug-induced pruritus; (3) neurological diseases; (4) psychiatric/psychosomatic diseases; (5) mixed; and (6) others. Based on its duration, itch can be divided into acute (less than 6 weeks) and chronic (more than 6 weeks).

In the skin, the perception of itch originates from the combined action of nervous, cutaneous and inflammatory cells and substances released by them in the microenvironment. In humans, the nerves responsible for the perception of itch also react to stimuli of pain. There are two types of pruriceptors, specialized nerve fibers sensing itch: fastly conducting A-fibers and non-myelinated, slowly conducting C-fibers, which can be further subdivided based on their responsiveness to different chemical or physical stimuli [reviewed in detail in].

The itch-specific peripheral sensory neurons may be a subgroup of nociceptive neurons. Subsets of mechano-insensitive nociceptive C-fibers can respond to histamine resulting in the release neuropeptides, including substance P and calcitonin gene -related peptide (CGRP). Instead, the mechano/heat-sensitive nociceptors are not reactive to histamine, but show a response to a cowhage plant protease, leading to stinging itch, which is possibly mediated via protease-activated receptor-2 or -4 (PAR-2 or -4). This type of stinging itch resembles that in skin inflammatory diseases. Nevertheless, cutaneous nerves contain a range of different receptors and ion channels. Therefore, different combinations of receptors may produce a certain type of itch and/or pain sensation. In the spinal dorsal horn, gastrin-releasing peptide-expressing neurons participate in the transmission of itch. The sensing system is further complexed by excitatory interneurons, spinothalamic tract neurons and the central nervous system where these sensations are recognized. Furthermore, it is noteworthy that chronic inflammation in skin causes additional changes to the neural and proinflammatory cell network.

Free nerve endings in the epidermis are important for sensing itch. It has been proposed that there is a reciprocal synaptic-like interaction between nerves and keratinocytes. One possible mediator in this interaction is ß-endorphin, as keratinocytes expressing this mediator have been found around unmyelinated fibers that can be activated via μ-opioid receptor. In fact, the whole complex of nerve fibers and the epidermal cells have been proposed to form the “itch receptor”. The skin cells themselves express a wide array of mediators and their receptors involved in the perception of itch. In addition to nerve fibers and epidermal cells, the cells of the immune system constitute yet another part in pruritus. In regard to cellular events in itching skin, mast cells are important players that are involved in neurogenic inflammation and its associated itch. In this review, the fundamental role of mast cells and sensory nerves in itch is discussed.

ITCH-Related Properties of Mast Cells

Mast cells are important effector cells in allergic reactions and immunity [reviewed in ], but they also contribute to carcinogenesis. Mast cells are abundant in body-environment interfaces in the skin and the gastrointestinal tract as well as present in the meninges of the central nervous system, and in the lung. In the skin, mast cell numbers are highest in the upper dermis and their numbers are not affected by age or sex, but increase in response to various environmental stimuli as shown after ultraviolet radiation in human skin, and after exposure to topical sensitizing agents in mice. It is thus obvious that mast cells constitute an inherent component of itch.

Mast cells are fully loaded with preformed mediators or they produce newly-synthesized mediators, including proteases, histamine, lipid-derived mediators, cytokines, and chemokines which they release upon activation through a variety of mechanisms leading to degranulation, piecemeal degranulation, and/or mediator secretion without degranulation [reviewed in and in ]. In type I hypersensitivity, mast cell degranulation is a fundamental event and involves crosslinking of an antigen with two IgE molecules bound to FcεRI receptors. Mast cell activation has been studied especially in the context of urticaria. It is known that several factors such as infections, stress, certain foods, pseudoallergens, hormones, neuropeptides, and Th2 inflammation may prime mast cells [reviewed in ]. Also autoimmune mechanisms may lead to mast cell activation. In these cases, IgE recognizes dermis-derived autoantigens, of which more than 200 are present in chronic spontaneous urticaria. Another mechanism is the presence of IgG or IgM class antibodies against IgE or against its FcεRI receptor. These autoantibodies may also target the eosinophils, which release mast-cell activating factors.

ITCH-Related Factors Released by Mast Cells

Mast cells release the contents of their secretory granules to their surroundings upon degranulation. Many of these granule mediators or mediators synthesized de novo participate in the development of itch.

Histamine and Its H1 and H4 Receptors

Histamine is the most important pruritogenic mediator of mast cells. Histamine has four receptors, namely H1–H4, of which H1 and H4 are important in pruritus. The function of these receptors in itch has been mainly studied in mouse models, and it has been shown that skin sensory neurons express H1, H3 and H4. In mouse models, H1-antagonists have been effective in decreasing itch, which has been known already for decades, although H4-antagonists have proved to be more potent. Histamine acts also on Transient receptor potential vanilloid receptor-1 (TRPV-1) in sensory neurons. In keratinocytes, also TRPV-4 is a histaminergic pruriceptor.

Tryptase and PAR-2

Tryptase, one of the main proteinases secreted by mast cells, can induce pruritus in mice and its effects are inhibited by PAR-2 antibody or PAR-2 antagonist, showing that PAR-2 is involved in tryptase-induced pruritus. Involvement of tryptase and PAR-2 in itch has also been reported in a mouse model of atopic dermatitis. In line with these data, non-lesional and lesional skin biopsies from patients with atopic dermatitis show PAR-2 in sensory nerves with closely located mast cells.

IL-31 and Its Receptor IL-31RA

Interleukin-31 (IL-31) is important in the pruritus of atopic dermatitis and it also participates in the itch of cutaneous lymphoma. IL-31 has been shown to increase the growth and sprouting of cutaneous sensory nerves, which express its receptor, IL-31RA.

Interleukin-31 has been demonstrated to induce mild itch that appears slowly starting at 143 min after skin prick test, which is associated with a long-lasting erythema. By comparison, histamine induces immediate itch that starts within 5 min after skin prick test. Human mast cells and T-cells are sources of IL-31 in skin, thus participating in the development of itch. Moreover, mast cell-derived histamine in addition to IL-31 increase the secretion of brain-derived natriuretic peptide, which in turn affects dendritic cells and keratinocytes to produce cytokines and other mediators, leading to inflammation, and increased itch signaling.

Leukotrienes and Prostaglandins

Leukotrienes and prostaglandins are also involved in itch, but by different mechanism. When administered intradermally, leukotriene B4 induces itch while prostaglandin E2 does not. Leukotriene B4 is released from keratinocytes in response to PAR-2 receptor activation and it is involved in the itch-causing cascades of substance P and IL-31. PAR-2 activation and leukotriene B4 release participate also in dermatophyte-induced itch. In addition to producing leukotriene B4 by themselves, human, and murine mast cells also express leukotriene B4 receptors BLT1 and BLT2. On the contrary, prostaglandin D2, also produced by mast cells themselves, decreases histamine release from mast cells and inhibits scratching in a mouse model. Thus, it seems that mast cells release many mediators that also control their own function.

Neuropeptides and Mast Cell Activation

There are several neuropeptides released by the sensory neurons in the skin, which then activate mast cells. Mast cells degranulate in response to nerve growth factor (NGF) and this signaling acts through TrkA tyrosine receptor. Interestingly, mast cells can secrete NGF also by themselves suggesting an autocrine or paracrine mechanism.

The potency of substance P in degranulating mast cells and causing itchy wheals was found already decades ago. The effects of substance P on mast cells are mediated either through neurokinin-1 receptor (NK-1R) or Mas-related G protein coupled receptor-X2 (MRGPRX2). In the initial phases of topical therapy with calcineurin inhibitors pimecrolimus and tacrolimus, pruritus and burning is often present. These compounds have been shown to release substance P and CGRP from primary afferent nerve endings in murine skin, leading to mast cell degranulation and thus release of pruritogenic histamine, and tryptase. Mast cells degranulate rapidly in response to substance P resulting in wheal reaction in the skin. The ability of substance P to induce histamine release seems to appear only at high concentrations. In line with this, substance P decreases mast cell recruitment and degranulation when used as a topical treatment in a murine model of atopic dermatitis, pointing to a concentration-dependent dual role of substance P.

Interestingly, stimulation of human mast cells with substance P and an IL-1 family member, IL-33, increase the secretion of proinflammatory TNF and IL-1β and these responses are inhibited by a natural flavonoid, methoxyluteolin. A pure luteolin with Ashwagandha has been proposed as a relief to patients suffering from stress and inflammation-associated diseases. This release of cytokines is potentially inhibited also by IL-37, another IL-1 family cytokine [reviewed in,, ]. The effect of substance P to release proinflammatory cytokines from mast cells points to a mechanism how mast cells participate in the neurogenic inflammation in psoriasis and atopic dermatitis as discussed below in more detail. Recently, reported increased levels of IL-33 in the stratum corneum of patients with atopic dermatitis. All these data emphasize the role of these cytokines in the context of neuroinflammation and itch, in which mast cells obviously participate.

Vasoactive intestinal peptide (VIP) is another potent neuropeptide to degranulate mast cells, a reaction mediated through VPAC2, and/or MRGPRX2 receptors on mast cells. In addition, substance P and VIP have been found to stimulate human mast cells in vitro conditions to release cytokines and chemokines, including TNF-α, GM-CSF, IL-3, CCL2, CCL5, CXCL8, CXCL9, and CXCL10.

Mast Cells, Skin Diseases, and ITCH

In a retrospective study conducted by, dermatological disease was the probable cause of the itch in 41,8 % of patients, while almost a similar number of cases (44,8 %) showed no apparent origin of the symptoms. The role of mast cells in the development of itch has been studied mostly in psoriasis, atopic dermatitis and urticaria. It is likely that the increased contacts between nerve fibers and mast cells often seen in these dermatoses constitute the morphological basis for itch chronicization during chronic skin inflammation. The current understanding of the role of mast cells and sensory nerves in itch in these and selected other pruritic dermatoses is discussed here next.

Mast Cells, Sensory Nerves, and Itch in Psoriasis

Psoriasis, a common chronic inflammatory and scaly skin disease, is characterized by pruritus that affects 60–90% of the patients and can appear in different forms, such as stinging, pinching, tickling, crawling, burning or pain sensations. On the other hand, psychosocial stress can exacerbate psoriasis in 40–80% of the patients. Thus, pruritus and stress may be reciprocally interconnected factors in psoriasis.

Emotional stress is associated with the activation of a variety of neuro-immune-endocrine systems. For example, the hypothalamic-pituitary-adrenal (HPA) axis is activated and stress hormones are released, including corticotroping-releasing hormone (CRH), adrenocorticotropic hormone, and glucocorticoids. Interestingly, human skin has its own functional peripheral equivalent of the HPA axis. Furthermore, numerous other factors are activated in stress, such as α-MSH, neuropeptides, neurotrophins and the sympathetic nervous system.

Several studies have previously shown that sensory nerve fibers and neuropeptides, including substance P, neurokinin A and VIP, are increased in the psoriatic lesion. Furthermore, the morphologic contacts between neurofilament+ nerves and tryptase+ mast cells are more frequent in psoriatic lesions than in non-lesional psoriatic skin or normal skin. Even the morphologic contacts between substance P+ and CGRP+ fibers and tryptase+ mast cells, but not the contacts between VIP+ fibers and tryptase+ mast cells, have been found to be increased in the psoriatic lesion. Therefore, there is a morphologic basis for mast cell-neural interaction as well as neurogenic inflammation in psoriasis.

The increase in mast cell numbers, especially the MCTC-type (tryptase+ and chymase+) of mast cell, in the psoriatic lesion has been known for decades. However, in contrast to the resistant tryptase, chymase is sensitive to the action of serum protease inhibitors, which may explain the finding that the enzyme activity of chymase is decreased in the psoriatic lesion. The net outcome of the partial inactivation of chymase may be an uncontrolled and enhanced substance P-mediated neurogenic inflammation, as chymase degrades substance P and VIP, but tryptase degrades VIP and CGRP. Tryptase has the capability to cleave and activate the PAR-2 receptor. Therefore, the serine proteinase may not only activate the receptor on nerves and numerous proinflammatory cells but it may activate PAR-2 on mast cells themselves in a para- or autocrine fashion, as the percentage of tryptase+ mast cells containing PAR-2 immunoreactivity is increased in the psoriatic lesion. Furthermore, the activation of PAR-2 sensitizes TRPV-1 leading to increased substance P and CGRP release and TRPV-1 is expressed in substance P+ fibers as well as in mast cells in human skin.

In addition to neuropeptides, the emotional stress in psoriasis may transmit its signals to the skin through CRH and CRH-R1 receptor on mast cells as suggested previously. This hypothesis is supported by a report that the immunostaining of CRH is increased in the epidermis, sweat glands, and hair follicles in the psoriatic lesion. In addition, we have analyzed the expression of CRH-R1 immunoreactivity in mast cells in psoriasis and found that the percentage of tryptase+ mast cells expressing CRH-R1 is higher in the lesional than non-lesional skin of 8 psoriatic patients (Haimakainen S et al., unpublished results).

There are several studies that have investigated molecular differences in skin between pruritic and non-pruritic-type of psoriasis. For example, the pruritic-type of psoriasis is characterized by increased levels of substance P and nerve fibers; decreased levels substance P-degrading neutral endopeptidase; increased levels of NGF and/or its receptor TrkA, decreased expression of semaphorin-3A (an axon-guidance molecule), and increased numbers of total and degranulated mast cells.

Mast Cells, Sensory Nerves, and Itch in Atopic Dermatitis

Atopic dermatitis (AD) is a well-known chronic eczematous skin disease characterized by distressing pruritus that can be exacerbated by inflammatory mediators, sensory nerves, skin dryness, heat, sweat, and emotional stress.

Like in the case of psoriasis, mast cells and sensory nerves have been suggested to play a role in neurogenic inflammation and itch in AD. Regarding mast cells, there are similarities between these diseases. In the lesional atopic dermatitis skin, the number of tryptase+ mast cells is increased slightly, but the activity of chymase is decreased. Like in psoriasis, the possible explanation for the partial inactivation of chymase in AD is the presence of chymase inhibitors in mast cells. The reduced chymase activity means that the enzyme cannot degrade and control efficiently a variety of proinflammatory peptides and proteins, including IL-6, IL-13, TNF-α, IL-4, IL-5, substance P, and VIP.

This is relevant for the inflammation, as the percentage of mast cells expressing TNF-α, IL-4, IL-6, and CD30 ligand is increased in the lesional AD skin. In addition, the severity of itching and tryptase+ and IL-6+ mast cells correlate inversely with the (pro)filaggrin immunostaining in the epidermis of AD skin.

Like in the case of psoriasis, there is an increased sensory nerve density in the epidermis and dermis in AD lesions, which suggests an enhanced neurogenic inflammation. Previously, it has been demonstrated that there is an increased expression of NGF and amphiregulin in the epidermis, but decreased expression of nerve repulsion factors, semaphorin-3A and anosmin-1, in AD lesions, which can explain the increased nerve density in AD. In addition, another explanation for the increased nerve density is the finding that the expression of NGF is elevated in mast cells in AD lesions, and mast cells can express the receptor of NGF, i.e., TrkA. There are also other regulatory mechanisms between NGF and tryptase, as NGF treatment of mast cells in vitro can increase the expression of TrkA as well as the contents of tryptase and histamine, and tryptase can generate mature NGF from pro-NGF. These molecular interactions can explain, at least in part, the finding that the morphologic contacts between tryptase+ mast cells and neurofilament+ fibers are increased in AD lesions.

Acute psychologic stress can result in marked changes in nerves, neuropeptides and mast cells. For example, the exposure of AD patients to acute Trier social stress test (TSST) associated with decreased NGF+ and PGP9.5+ fibers and decreased contacts between PGP9.5+ fibers and tryptase+ mast cells in AD lesions. However, in the non-lesional AD skin, these parameters increased, rather than decreased. Moreover, a positive correlation was observed between itch and mast cell-nerve fiber contacts in the non-lesional AD skin after TSST or lesional AD skin before TSST.

The classic histaminergic itch is mediated via H1-receptors on cutaneous sensory nerves, though H4-receptors on nerves can also be involved in pruritus. However, antihistamines usually are not effective in relieving distressing pruritus in chronic skin inflammation. The reason is the non-histaminergic itch that can be mediated through other distinct pathways. The PAR-2 activation on sensory fibers is one of them, as PAR-2+ fibers are increased in AD lesions. Therefore, tryptase released from mast cells can activate PAR-2 on nerve fibers with subsequent release of substance P and CGRP and potentiation of neurogenic inflammation. Interestingly, lichenified lesions of atopic dermatitis showed no staining for substance P or VIP nor degranulated mast cells, suggesting that other factors may contribute to pruritus in chronic, lichenified lesions.

Interleukin-31 can represent another pathway for non-histaminergic itch in AD. This cytokine is derived from Th2 cells and mast cells. In the psoriatic and AD lesions, mast cells show increased levels of IL-31 immunoreactivity compared to normal skin. The expressions of the mRNA of IL-31 and its receptor IL-31RA are increased in AD, but not psoriatic, lesions. Furthermore, the receptor is located in small-diameter neurons of human dorsal root ganglia.

Interleukin-31 may not only induce slowly developing itch, but it may also increase the elongation, branching and density of nerves in AD lesions.

Mast Cells, Sensory Nerves, and Itch in Urticaria

Urticaria is a fundamentally mast cell-driven disease, in which pruritus is a key symptom in addition to wheals and/or angioedema. In urticaria, it is the degranulation of mast cells and release of their mediators that cause the symptoms by activating sensory nerves and causing vasodilatation and plasma extravasation. Although the details of mast cell activation in urticaria are not known yet, mast cells may be activated in urticaria by allergens/autoallergens or IgG antibodies against IgE or its receptor. In patients with chronic urticaria, more than 200 autoantigens reacting with IgE have been detected and of these, IL-24 is a common and functional autoantigen recognized by IgE antibodies.

Interestingly, also a plethora of other agents are known to prime mast cells for further activation [reviewed in ]. Recently, a mouse model showed that Mrgprb2, the ortholog of the human MRGPRX2, and might be a mast cell-specific key receptor in pseudoallergic reactions. This receptor is upregulated in the skin of patients with severe chronic urticaria.

Mast Cells, Sensory Nerves, and Itch in Selected Other Dermatoses

Prurigo nodularis (PN) is a typical example of an itchy dermatosis. The close contact of mast cells and nerve fibers in PN lesions was reported already 20 years ago by. They also noticed that there are increased mast cell numbers in the lesions. There are several other pruritic skin diseases, in which the changes in mast cell numbers have been investigated and they definitely participate in the pathogenesis, although the exact details of their role in pruritus in these dermatoses is not clear yet. Mast cell numbers are increased already in the perilesional skin in patients with hidradenitis suppurativa (HS) and the numbers are further elevated in early and chronic lesions. In line with this finding, about 60 % of patients with HS report moderate or severe pruritus. Similarly, more than one third of patients with basal cell carcinoma or squamous cell carcinoma report to have pruritus and elevated mast cell numbers in both tumors have been reported. The connection between mast cell numbers and itch is not so clear in melanoma, in which less patients report itch and both increased, and decreased mast cell numbers have been reported. However, since the exact functions of mast cells in skin cancers are not known at the moment, also their role in itch remains unclear.

Animal Models in Research on Mast Cells and Itch

The growing research performed in experimental animals has revealed that the molecular mechanisms of pruritus as well as the ligands and receptors involved in itch induction are more complex than thought, and it is beyond the scope if this review to describe them all.

Animal models to study pruritus have been mainly developed for AD. Subcutaneous capsaicin injections to neonatal rats causes long-lasting, pruritic skin changes with histopathological findings resembling AD, including increased mast cell number. The Kyoto Fancy Rat Stock 4 is another rat model of AD showing spontaneous itchy dermatitis with increased transepidermal water loss and mast cell numbers. The bile duct ligation rat model of liver disease has provided a good insight to neuroinflammation and itch. In these rats, PAR-2 receptors are activated and this potentiates the TRPV-1 channels. As discussed above, mast cell tryptase may activate PAR-2, pointing to a role for mast cells also in hepatic pruritus. Elevated tryptase and PAR-2 levels are also found in a mouse model with ovalbumin-induced AD-like dermatitis. Mast cells and sensory nerves can be found in apparent morphologic contact in the skin. For example, in a mouse model of hapten-induced AD, mast cells in the lesional skin express high levels of cell adhesion molecule-1 (CADM-1), a molecule that was found to enhance adhesion and communication between sensory nerves and mast cells in vitro. Human mast cells have also been found to express CADM-1 that probably interacts with nectin-3 on nerves.

The interaction between nerve fibers and mast cells can be affected by molecules leading to decreased itch and inflammation. In the NC/Nga mouse model of AD, dorsal skin lesions develop spontaneously. The treatment of these lesions with intracutaneous injections of semaphorin-3A, a nerve repulsion factor, for 5 days followed by biopsing on day 11 revealed a significant reduction in the clinical skin score and scratching behavior, decrease in PGP9.5+ nerve fibers in the epidermis, decrease in mast cell numbers, infiltrating CD4+ T cells, IL-4 production, and epidermal thickness. In addition, oral administration of chymase inhibitor has been shown to ameliorate dermatitis as well as scratching behavior in these NC/Nga mice.

In pruritus, the neuroendocrine signals may travel from the central nervous system to periphery and vice versa. showed in 80’s that rats exposed to both audiovisual cue and antigen injection were conditioned to mast cell protease II release after reexposure to the audiovisual cue only. A sonic stress for 24 h in mice can induce degranulation of mast cells, changes in endothelium, increase in substance P+ fibers and their contacts with mast cells, and increase in the expression of NGF in skin mast cells. Furthermore, skin mast cells in rats can be activated by stress induced by immobilization. In summary, there is compelling in vivo-evidence that show activation of mast cells induced by stress.

In an AD model induced by IL-13 in mice, the scratching behavior evoked by itch associated with increase in PGP9.5+, CGRP+, and TRPA-1+ (transient receptor potential ankyrin (1) nerves, mast cells, and particularly in TRPA-1+ mast cells. However, there was no increase in TRPV-1 in inflamed skin. In line with this, TRPA-1+ mast cells and nerves and the contacts between them were increased in the lesional skin of patients with AD. Therefore, this study emphasizes the role of TRPA-1 in itch associated with skin inflammation. In contrast to this, itch evoked by intradermal injections of β2-microglobulin in mouse skin is related, at least in part, to TRPV-1+ primary sensory nerves. Furthermore, itch evoked by IL-31 injections in mice is related to both TRPV-1 and TRPA-1 using knockout mouse models. In addition, itch induced in mice by lysophosphatidic acid-injections is related to both cation channels.

Conclusion and Future Challenges

Despite thorough and extensive research on mast cells during the past decades, these cells still remain to be an intriguing, complex cell type present in our body-environment interfaces. Although mast cells are physiologically meant to stay alert and to react to potentially noxious agents and conditions, their reactions may turn harmful. In several disorders, their functions seem to increase itch, which is not always beneficial to the host.

The complex functional and morphologic interaction between mast cells and sensory nerves is summarized and illustrated in Figure 1. Psychic stress can aggravate itch in several skin diseases. Although the mechanism is not clear in detail, the activation of the systemic HPA axis and/or its equivalent in the skin as well as the activation of neural response can play a role in activating the neurogenic inflammation in the skin. As a consequence, several neuroendocrine mediators, including CRH, substance P and NGF, are released to the circulation and/or are produced locally in the skin. These mediators lead to activation of mast cells and release of their proinflammatory mediators that modify the inflammation of the skin disorder, often increasing itch. The mechanisms are complex owing to the intimate reciprocal communication between mast cells and sensory nerves resulting in increase in mast cell numbers and nerve fibers, development of a vicious circle, and exacerbation of neurogenic inflammation and pruritus.

Future research should aim at further elucidating the details of mast cell biology in different physiological and pathological skin conditions in humans. Here, it will be important to focus on the association of psychic stress with mast cell-neural functions in patients with psoriasis or atopic dermatitis under standardized stress conditions. We should also aim at more in-depth understanding of mast cell heterogeneity and recruitment to the skin and how these may affect mast cell-neural responses in chronic pruritic disorders. In addition, the inhibitors of mast cell mediators or drugs preventing mast cell activation may provide new therapeutic options to treat distressing itch and thereby improve the quality of life of patients.

Author Contributions

Both authors wrote and edited the text.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 153

  1. 1.

    Ackermann L. Harvima I. T. (1998 ). Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch. Dermatol. Res. 290 353–359.

    Not in our library10.1007/s004030050317

  2. 2.

    Albisetti G. W. Pagani M. Platonova E. Hosli L. Johannssen H. C. Fritschy J. M. (2019 ). Dorsal horn gastrin-releasing peptide expressing neurons transmit spinal itch but not pain signals. J. Neurosci. 39 2238–2250.

    Not in our library10.1523/jneurosci.2559-18.2019

  3. 3.

    Amadesi S. Nie J. Vergnolle N. Cottrell G. S. Grady E. F. Trevisani M. (2004 ). Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J. Neurosci. 24 4300–4312.

    Not in our library10.1523/jneurosci.5679-03.2004

  4. 4.

    Amatya B. El-Nour H. Holst M. Theodorsson E. Nordlind K. (2011 ). Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br. J. Dermatol. 164 1023–1029.

    Not in our library10.1111/j.1365-2133.2011.10241.x

  5. 5.

    Andoh T. Harada A. Kuraishi Y. (2017a ). Involvement of leukotriene B4 released from keratinocytes in itch-associated response to intradermal interleukin-31 in mice. Acta Derm. Venereol. 97 922–927.

    Not in our library10.2340/00015555-2697

  6. 6.

    Andoh T. Maki T. Li S. Uta D. (2017b ). beta2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur. J. Pharmacol. 810 134–140.

    Not in our library10.1016/j.ejphar.2017.07.007

  7. 7.

    Andoh T. Katsube N. Maruyama M. Kuraishi Y. (2001 ). Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J. Invest. Dermatol. 117 1621–1626.

    Not in our library10.1046/j.0022-202x.2001.01585.x

  8. 8.

    Andoh T. Kuraishi Y. (1998 ). Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur. J. Pharmacol. 353 93–96.

    Not in our library10.1016/s0014-2999(98)00440-3

  9. 9.

    Andoh T. Takayama Y. Kuraishi Y. (2014 ). Involvement of leukotriene B4 in dermatophyte-related itch in mice. Pharmacol. Rep. 66 699–703.

    Not in our library10.1016/j.pharep.2014.01.003

  10. 10.

    Arck P. C. Slominski A. Theoharides T. C. Peters E. M. Paus R. (2006 ). Neuroimmunology of stress: skin takes center stage. J. Invest. Dermatol. 126 1697–1704.

    Not in our library10.1038/sj.jid.5700104

  11. 11.

    Azimi E. Xia J. Lerner E. A. (2016 ). Peripheral mechanisms of itch. Curr. Probl. Dermatol. 50 18–23.

    Not in our library10.1159/000446012

  12. 12.

    Back S. K. Jeong K. Y. Li C. Lee J. Lee S. B. Na H. S. (2012 ). Chronically relapsing pruritic dermatitis in the rats treated as neonate with capsaicin; a potential rat model of human atopic dermatitis. J. Dermatol. Sci. 67 111–119.

    Not in our library10.1016/j.jdermsci.2012.05.006

  13. 13.

    Baraniuk J. N. (2012 ). Rise of the sensors: nociception and pruritus. Curr. Allergy Asthma Rep. 12 104–114.

    Not in our library10.1007/s11882-012-0245-8

  14. 14.

    Basavaraj K. H. Navya M. A. Rashmi R. (2011 ). Stress and quality of life in psoriasis: an update. Int. J. Dermatol. 50 783–792.

    Not in our library10.1111/j.1365-4632.2010.04844.x

  15. 15.

    Belghiti M. Estevez-Herrera J. Gimenez-Garzo C. Gonzalez-Usano A. Montoliu C. Ferrer-Montiel A. (2013 ). Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease. J. Biol. Chem. 288 9675–9685.

    Not in our library10.1074/jbc.m113.455162

  16. 16.

    Bigliardi-Qi M. Sumanovski L. T. Buchner S. Rufli T. Bigliardi P. L. (2004 ). Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 209 183–189.

    Not in our library10.1159/000079887

  17. 17.

    Biswas A. Richards J. E. Massaro J. Mahalingam M. (2014 ). Mast cells in cutaneous tumors: innocent bystander or maestro conductor? Int. J. Dermatol. 53 806–811.

    Not in our library10.1111/j.1365-4632.2012.05745.x

  18. 18.

    Bo L. Mork S. J. Nyland H. (1992 ). An immunohistochemical study of mononuclear cells in meningiomas. Neuropathol. Appl. Neurobiol. 18 548–558.

    Not in our library10.1111/j.1365-2990.1992.tb00825.x

  19. 19.

    Bradding P. Walls A. F. Holgate S. T. (2006 ). The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117 1277–1284.

    Not in our library10.1016/j.jaci.2006.02.039

  20. 20.

    Caraffa A. Conti C. D Ovidio C. Gallenga C. E. Tettamanti L. Mastrangelo F. (2018 ). New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators. J. Biol. Regul. Homeost. Agents 32 449–454.

    Not in our library

  21. 21.

    Carvalho R. F. Nilsson G. Harvima I. T. (2010 ). Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. Exp. Dermatol. 19 117–122.

    Not in our library10.1111/j.1600-0625.2009.00998.x

  22. 22.

    Caughey G. H. Leidig F. Viro N. F. Nadel J. A. (1988 ). Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J. Pharmacol. Exp. Ther. 244 133–137.

    Not in our library

  23. 23.

    Cevikbas F. Wang X. Akiyama T. Kempkes C. Savinko T. Antal A. (2014 ). A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA. J. Allergy Clin. Immunol. 133 448–460.

    Not in our library10.1016/j.jaci.2013.10.048

  24. 24.

    Chang S. E. Han S. S. Jung H. J. Choi J. H. (2007 ). Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br. J. Dermatol. 156 1272–1277.

    Not in our library10.1111/j.1365-2133.2007.07935.x

  25. 25.
    Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch · 2016
    No notice
  26. 26.

    Choi H. Kim D. J. Nam S. Lim S. Hwang J. S. Park K. S. (2018 ). Manifestation of atopic dermatitis-like skin in TNCB-induced NC/Nga mice is ameliorated by topical treatment of substance P, possibly through blockade of allergic inflammation. Exp. Dermatol. 27 396–402.

    Not in our library10.1111/exd.13421

  27. 27.

    Church M. K. Kolkhir P. Metz M. Maurer M. (2018 ). The role and relevance of mast cells in urticaria. Immunol. Rev. 282 232–247.

    Not in our library10.1111/imr.12632

  28. 28.

    Conti P. Caraffa A. Kritas S. K. Ronconi G. Lessiani G. Toniato E. (2017 ). Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues. J. Biol. Regul. Homeost. Agents 31 263–267.

    Not in our library

  29. 29.

    da Silva E. Z. Jamur M. C. Oliver C. (2014 ). Mast cell function: a new vision of an old cell. J. Histochem. Cytochem. 62 698–738.

    Not in our library10.1369/0022155414545334

  30. 30.

    Diaconu N. C. Kaminska R. Naukkarinen A. Harvima R. J. Harvima I. T. (2007 ). The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 21 908–915.

    Not in our library10.1111/j.1468-3083.2006.02100.x

  31. 31.

    Dillon S. R. Sprecher C. Hammond A. Bilsborough J. Rosenfeld-Franklin M. Presnell S. R. (2004 ). Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 5 752–760.

    Not in our library10.1038/ni1084

  32. 32.

    Dunford P. J. Williams K. N. Desai P. J. Karlsson L. McQueen D. Thurmond R. L. (2007 ). Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 119 176–183.

    Not in our library10.1016/j.jaci.2006.08.034

  33. 33.

    Eedy D. J. Johnston C. F. Shaw C. Buchanan K. D. (1991 ). Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J. Invest. Dermatol. 96 434–438.

    Not in our library10.1111/1523-1747.ep12469898

  34. 34.

    Feld M. Garcia R. Buddenkotte J. Katayama S. Lewis K. Muirhead G. (2016 ). The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J. Allergy Clin. Immunol. 138 500.e24–508.e24.

    Not in our library10.1016/j.jaci.2016.02.020

  35. 35.

    Fischer M. Harvima I. T. Carvalho R. F. Moller C. Naukkarinen A. Enblad G. (2006 ). Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J. Clin. Invest. 116 2748–2756.

    Not in our library10.1172/jci24274

  36. 36.

    Fjellner B. Hägermark O. (1981 ). Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters. Acta Derm. Venereol. 61 245–250.

    Not in our library

  37. 37.

    Franconi G. M. Graf P. D. Lazarus S. C. Nadel J. A. Caughey G. H. (1989 ). Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J. Pharmacol. Exp. Ther. 248 947–951.

    Not in our library

  38. 38.

    Fujisawa D. Kashiwakura J. Kita H. Kikukawa Y. Fujitani Y. Sasaki-Sakamoto T. (2014 ). Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J. Allergy Clin. Immunol. 134 622.e9–633.e9.

    Not in our library10.1016/j.jaci.2014.05.004

  39. 39.

    Furuno T. Hagiyama M. Sekimura M. Okamoto K. Suzuki R. Ito A. (2012 ). Cell adhesion molecule 1 (CADM1) on mast cells promotes interaction with dorsal root ganglion neurites by heterophilic binding to nectin. J. Neuroimmunol. 250 50–58.

    Not in our library10.1016/j.jneuroim.2012.05.016

  40. 40.

    Gallenga C. E. Pandolfi F. Caraffa A. Kritas S. K. Ronconi G. Toniato E. (2019 ). Interleukin-1 family cytokines and mast cells: activation and inhibition. J. Biol. Regul. Homeost. Agents 33 1–6.

    Not in our library

  41. 41.

    Greaves M. W. (2010 ). Pathogenesis and treatment of pruritus. Curr. Allergy Asthma Rep. 10 236–242.

    Not in our library10.1007/s11882-010-0117-z

  42. 42.

    Grimbaldeston M. A. Simpson A. Finlay-Jones J. J. Hart P. H. (2003 ). The effect of ultraviolet radiation exposure on the prevalence of mast cells in human skin. Br. J. Dermatol. 148 300–306.

    Not in our library10.1046/j.1365-2133.2003.05113.x

  43. 43.

    Groneberg D. A. Serowka F. Peckenschneider N. Artuc M. Grutzkau A. Fischer A. (2005 ). Gene expression and regulation of nerve growth factor in atopic dermatitis mast cells and the human mast cell line. J. Neuroimmunol. 161 87–92.

    Not in our library10.1016/j.jneuroim.2004.12.019

  44. 44.

    Gruber B. L. Baeza M. L. Marchese M. J. Agnello V. Kaplan A. P. (1988 ). Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J. Invest. Dermatol. 90 213–217.

    Not in our library10.1111/1523-1747.ep12462239

  45. 45.

    Gupta K. Harvima I. T. (2018 ). Mast cell-neural interactions contribute to pain and itch. Immunol. Rev. 282 168–187.

    Not in our library10.1111/imr.12622

  46. 46.

    Gurish M. F. Austen K. F. (2001 ). The diverse roles of mast cells. J. Exp. Med. 194 F1–F5.

    Not in our library10.1084/jem.194.1.f1

  47. 47.

    Hägermark O. Hökfelt T. Pernow B. (1978 ). Flare and itch induced by substance P in human skin. J. Invest. Dermatol. 71 233–235.

    Not in our library10.1111/1523-1747.ep12515092

  48. 48.

    Hagiyama M. Inoue T. Furuno T. Iino T. Itami S. Nakanishi M. (2013 ). Increased expression of cell adhesion molecule 1 by mast cells as a cause of enhanced nerve-mast cell interaction in a hapten-induced mouse model of atopic dermatitis. Br. J. Dermatol. 168 771–778.

    Not in our library10.1111/bjd.12108

  49. 49.

    Haimakainen S. Kaukinen A. P. Suttle M. M. Pelkonen J. Harvima I. T. (2017 ). CD40 ligand is increased in mast cells in psoriasis and actinic keratosis but less so in epithelial skin carcinomas. Cancer Invest. 35 143–151.

    Not in our library10.1080/07357907.2017.1289216

  50. 50.

    Harvima I. T. Levi-Schaffer F. Draber P. Friedman S. Polakovicova I. Gibbs B. F. (2014 ). Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134 530–544.

    Not in our library10.1016/j.jaci.2014.03.007

  51. 51.

    Harvima I. T. Nilsson G. (2012 ). Stress, the neuroendocrine system and mast cells: current understanding of their role in psoriasis. Expert Rev. Clin. Immunol. 8 235–241.

    Not in our library10.1586/eci.12.1

  52. 52.

    Harvima I. T. Nilsson G. Suttle M. M. Naukkarinen A. (2008 ). Is there a role for mast cells in psoriasis? Arch. Dermatol. Res. 300 461–478.

    Not in our library10.1007/s00403-008-0874-x

  53. 53.

    Hashimoto Y. Arai I. Tanaka M. Nakaike S. (2005 ). Prostaglandin D2 inhibits IgE-mediated scratching by suppressing histamine release from mast cells. J. Pharmacol. Sci. 98 90–93.

    Not in our library10.1254/jphs.sc0040209

  54. 54.

    Hawro T. Saluja R. Weller K. Altrichter S. Metz M. Maurer M. (2014 ). Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 69 113–117.

    Not in our library10.1111/all.12316

  55. 55.

    Hide M. Francis D. M. Grattan C. E. Hakimi J. Kochan J. P. Greaves M. W. (1993 ). Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N. Engl. J. Med. 328 1599–1604.

    Not in our library10.1056/nejm199306033282204

  56. 56.

    Horigome K. Pryor J. C. Bullock E. D. Johnson E. M. Jr. (1993 ). Mediator release from mast cells by nerve growth factor. Neurotrophin specificity and receptor mediation. J. Biol. Chem. 268 14881–14887.

    Not in our library

  57. 57.

    Horsmanheimo L. Harvima I. T. Järvikallio A. Harvima R. J. Naukkarinen A. Horsmanheimo M. (1994 ). Mast cells are one major source of interleukin-4 in atopic dermatitis. Br. J. Dermatol. 131 348–353.

    Not in our library10.1111/j.1365-2133.1994.tb08522.x

  58. 58.

    Hu G. Wang S. Cheng P. (2018 ). Tumor-infiltrating tryptase(+) mast cells predict unfavorable clinical outcome in solid tumors. Int. J. Cancer 142 813–821.

    Not in our library10.1002/ijc.31099

  59. 59.

    Huttunen M. Harvima I. T. Ackermann L. Harvima R. J. Naukkarinen A. Horsmanheimo M. (1996 ). Neuropeptide- and capsaicin-induced histamine release in skin monitored with the microdialysis technique. Acta Derm. Venereol. 76 205–209.

    Not in our library10.2340/0001555576205209

  60. 60.

    Ilves T. Harvima I. T. (2015 ). Decrease in chymase activity is associated with increase in IL-6 expression in mast cells in atopic dermatitis. Acta Derm. Venereol. 95 411–416.

    Not in our library10.2340/00015555-1979

  61. 61.

    Ilves T. Tiitu V. Suttle M. M. Saarinen J. V. Harvima I. T. (2015 ). Epidermal expression of filaggrin/profilaggrin is decreased in atopic dermatitis: reverse association with mast cell tryptase and IL-6 but not with clinical severity. Dermatitis 26 260–267.

    Not in our library10.1097/der.0000000000000143

  62. 62.

    Järvikallio A. Harvima I. T. Naukkarinen A. (2003 ). Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch. Dermatol. Res. 295 2–7.

    Not in our library10.1007/s00403-002-0378-z

  63. 63.

    Järvikallio A. Naukkarinen A. Harvima I. T. Aalto M. L. Horsmanheimo M. (1997 ). Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br. J. Dermatol. 136 871–877.

    Not in our library10.1111/j.1365-2133.1997.tb03927.x

  64. 64.

    Kempkes C. Buddenkotte J. Cevikbas F. Buhl T. Steinhoff M. (2014 ). “Role of PAR-2 in neuroimmune communication and itch,” in Itch: Mechanisms and Treatment, eds Carstens E. Akiyama T. (Boca Raton, FL: CRC Press).

    Not in our library

  65. 65.

    Kim J. E. Cho D. H. Kim H. S. Kim H. J. Lee J. Y. Cho B. K. (2007 ). Expression of the corticotropin-releasing hormone-proopiomelanocortin axis in the various clinical types of psoriasis. Exp. Dermatol. 16 104–109.

    Not in our library10.1111/j.1600-0625.2006.00509.x

  66. 66.

    Kim M. S. Kim Y. K. Lee D. H. Seo J. E. Cho K. H. Eun H. C. (2009 ). Acute exposure of human skin to ultraviolet or infrared radiation or heat stimuli increases mast cell numbers and tryptase expression in human skin in vivo. Br. J. Dermatol. 160 393–402.

    Not in our library10.1111/j.1365-2133.2008.08838.x

  67. 67.

    Kitagaki H. Fujisawa S. Watanabe K. Hayakawa K. Shiohara T. (1995 ). Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J. Invest. Dermatol. 105 749–755.

    Not in our library10.1111/1523-1747.ep12325538

  68. 68.

    Kittaka H. Uchida K. Fukuta N. Tominaga M. (2017 ). Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV. J. Physiol. 595 2681–2698.

    Not in our library10.1113/jp273961

  69. 69.

    Kou K. Nakamura F. Aihara M. Chen H. Seto K. Komori-Yamaguchi J. (2012 ). Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm. Venereol. 92 521–528.

    Not in our library10.2340/00015555-1350

  70. 70.

    Kubanov A. A. Katunina O. R. Chikin V. V. (2015 ). Expression of neuropeptides, neurotrophins, and neurotransmitters in the skin of patients with atopic dermatitis and psoriasis. Bull. Exp. Biol. Med. 159 318–322.

    Not in our library10.1007/s10517-015-2951-4

  71. 71.

    Kulka M. Sheen C. H. Tancowny B. P. Grammer L. C. Schleimer R. P. (2008 ). Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123 398–410.

    Not in our library10.1111/j.1365-2567.2007.02705.x

  72. 72.

    Kuramoto T. Yokoe M. Tanaka D. Yuri A. Nishitani A. Higuchi Y. (2015 ). Atopic dermatitis-like skin lesions with IgE hyperproduction and pruritus in KFRS4/Kyo rats. J. Dermatol. Sci. 80 116–123.

    Not in our library10.1016/j.jdermsci.2015.09.005

  73. 73.

    LaMotte R. H. Dong X. Ringkamp M. (2014 ). Sensory neurons and circuits mediating itch. Nat. Rev. Neurosci. 15 19–31.

    Not in our library10.1038/nrn3641

  74. 74.

    Liang Y. Marcusson J. A. Jacobi H. H. Haak-Frendscho M. Johansson O. (1998 ). Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J. Cutan. Pathol. 25 189–198.

    Not in our library10.1111/j.1600-0560.1998.tb01718.x

  75. 75.

    Lundeen K. A. Sun B. Karlsson L. Fourie A. M. (2006 ). Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J. Immunol. 177 3439–3447.

    Not in our library10.4049/jimmunol.177.5.3439

  76. 76.

    MacQueen G. Marshall J. Perdue M. Siegel S. Bienenstock J. (1989 ). Pavlovian conditioning of rat mucosal mast cells to secrete rat mast cell protease II. Science 243 83–85.

    Not in our library10.1126/science.2911721

  77. 77.

    Matusiak L. Szczech J. Kaaz K. Lelonek E. Szepietowski J. C. (2018 ). Clinical characteristics of pruritus and pain in patients with Hidradenitis Suppurativa. Acta Derm. Venereol. 98 191–194.

    Not in our library10.2340/00015555-2815

  78. 78.

    McNeil B. D. Pundir P. Meeker S. Han L. Undem B. J. Kulka M. (2015 ). Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519 237–241.

    Not in our library10.1038/nature14022

  79. 79.

    Meng J. Moriyama M. Feld M. Buddenkotte J. Buhl T. Szollosi A. (2018 ). New mechanism underlying IL-31-induced atopic dermatitis. J. Allergy Clin. Immunol. 141 1677.e8–1689.e8.

    Not in our library10.1016/j.jaci.2017.12.1002

  80. 80.

    Mills K. C. Kwatra S. G. Feneran A. N. Pearce D. J. Williford P. M. D’Agostino R. B. (2012 ). Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. Arch. Dermatol. 148 1422–1423.

    Not in our library10.1001/archdermatol.2012.3104

  81. 81.

    Moiseeva E. P. Roach K. M. Leyland M. L. Bradding P. (2013 ). CADM1 is a key receptor mediating human mast cell adhesion to human lung fibroblasts and airway smooth muscle cells. PLoS One 8:e61579.

    Not in our library10.1371/journal.pone.0061579

  82. 82.

    Murakami M. Matsumoto R. Urade Y. Austen K. F. Arm J. P. (1995 ). c-kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synthase and increased IgE-dependent prostaglandin D2 generation in immature mouse mast cells. J. Biol. Chem. 270 3239–3246.

    Not in our library10.1074/jbc.270.7.3239

  83. 83.

    Murota H. Katayama I. (2017 ). Exacerbating factors of itch in atopic dermatitis. Allergol. Int. 66 8–13.

    Not in our library10.1016/j.alit.2016.10.005

  84. 84.

    Nakamura M. Toyoda M. Morohashi M. (2003 ). Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br. J. Dermatol. 149 718–730.

    Not in our library10.1046/j.1365-2133.2003.05586.x

  85. 85.

    Nakamura N. Tamagawa-Mineoka R. Yasuike R. Masuda K. Matsunaka H. Murakami Y. (2019 ). Stratum corneum interleukin-33 expressions correlate with the degree of lichenification and pruritus in atopic dermatitis lesions. Clin. Immunol. 201 1–3.

    Not in our library10.1016/j.clim.2019.02.006

  86. 86.

    Nattkemper L. A. Martinez-Escala M. E. Gelman A. B. Singer E. M. Rook A. H. Guitart J. (2016 ). Cutaneous T-cell Lymphoma and Pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm. Venereol. 96 894–898.

    Not in our library10.2340/00015555-2417

  87. 87.

    Naukkarinen A. Harvima I. Paukkonen K. Aalto M. L. Horsmanheimo M. (1993 ). Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch. Dermatol. Res. 285 341–346.

    Not in our library10.1007/bf00371834

  88. 88.

    Naukkarinen A. Harvima I. T. Aalto M. L. Harvima R. J. Horsmanheimo M. (1991 ). Quantitative analysis of contact sites between mast cells and sensory nerves in cutaneous psoriasis and lichen planus based on a histochemical double staining technique. Arch. Dermatol. Res. 283 433–437.

    Not in our library10.1007/bf00371778

  89. 89.

    Naukkarinen A. Nickoloff B. J. Farber E. M. (1989 ). Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J. Invest. Dermatol. 92 126–129.

    Not in our library10.1111/1523-1747.ep13071340

  90. 90.

    Nilsson G. Forsberg-Nilsson K. Xiang Z. Hallböök F. Nilsson K. Metcalfe D. D. (1997 ). Human mast cells express functional TrkA and are a source of nerve growth factor. Eur. J. Immunol. 27 2295–2301.

    Not in our library10.1002/eji.1830270925

  91. 91.

    Niyonsaba F. Ushio H. Hara M. Yokoi H. Tominaga M. Takamori K. (2010 ). Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J. Immunol. 184 3526–3534.

    Not in our library10.4049/jimmunol.0900712

  92. 92.

    Oh M. H. Oh S. Y. Lu J. Lou H. Myers A. C. Zhu Z. (2013 ). TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J. Immunol. 191 5371–5382.

    Not in our library10.4049/jimmunol.1300300

  93. 93.

    Ohsawa Y. Hirasawa N. (2014 ). The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol. Int. 63 533–542.

    Not in our library10.2332/allergolint.13-ra-0675

  94. 94.

    Owen J. Punt J. Stranford S. (eds) (2013 ). Kuby Immunology, 7th Edn New York, NY: Freeman W. H. & Company.

    Not in our library

  95. 95.

    Pavlovic S. Daniltchenko M. Tobin D. J. Hagen E. Hunt S. P. Klapp B. F. (2008 ). Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J. Invest. Dermatol. 128 434–446.

    Not in our library10.1038/sj.jid.5701079

  96. 96.

    Peters E. M. Kuhlmei A. Tobin D. J. Muller-Rover S. Klapp B. F. Arck P. C. (2005 ). Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav. Immun. 19 252–262.

    Not in our library10.1016/j.bbi.2004.08.005

  97. 97.

    Peters E. M. Liezmann C. Spatz K. Daniltchenko M. Joachim R. Gimenez-Rivera A. (2011 ). Nerve growth factor partially recovers inflamed skin from stress-induced worsening in allergic inflammation. J. Invest. Dermatol. 131 735–743.

    Not in our library10.1038/jid.2010.317

  98. 98.

    Peters E. M. Michenko A. Kupfer J. Kummer W. Wiegand S. Niemeier V. (2014 ). Mental stress in atopic dermatitis–neuronal plasticity and the cholinergic system are affected in atopic dermatitis and in response to acute experimental mental stress in a randomized controlled pilot study. PLoS One 9:e113552.

    Not in our library10.1371/journal.pone.0113552

  99. 99.

    Petra A. I. Tsilioni I. Taracanova A. Katsarou-Katsari A. Theoharides T. C. (2018 ). Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy Asthma Proc. 39 153–160.

    Not in our library10.2500/aap.2018.38.4105

  100. 100.

    Puccetti A. Bason C. Simeoni S. Millo E. Tinazzi E. Beri R. (2005 ). In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin. Exp. Allergy 35 1599–1607.

    Not in our library10.1111/j.1365-2222.2005.02380.x

  101. 101.

    Rajabi P. Bagheri A. Hani M. (2017 ). Intratumoral and peritumoral mast cells in malignant melanoma: an immunohistochemical study. Adv. Biomed. Res. 6:39.

    Not in our library10.4103/2277-9175.204592

  102. 102.

    Ribatti D. Ennas M. G. Vacca A. Ferreli F. Nico B. Orru S. (2003a ). Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 33 420–425.

    Not in our library10.1046/j.1365-2362.2003.01152.x

  103. 103.

    Ribatti D. Vacca A. Ria R. Marzullo A. Nico B. Filotico R. (2003b ). Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur. J. Cancer 39 666–674.

    Not in our library10.1016/s0959-8049(02)00150-8

  104. 104.

    Rossbach K. Nassenstein C. Gschwandtner M. Schnell D. Sander K. Seifert R. (2011 ). Histamine H1, H3 and H4 receptors are involved in pruritus. Neuroscience 190 89–102.

    Not in our library10.1016/j.neuroscience.2011.06.002

  105. 105.

    Saadalla A. M. Osman A. Gurish M. F. Dennis K. L. Blatner N. R. Pezeshki A. (2018 ). Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner. Proc. Natl. Acad. Sci. U.S.A. 115 1588–1592.

    Not in our library10.1073/pnas.1716804115

  106. 106.

    Saarinen J. V. Harvima R. J. Naukkarinen A. Horsmanheimo M. Harvima I. T. (2001 ). The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reaction in the skin. Clin. Exp. Allergy 31 593–601.

    Not in our library10.1046/j.1365-2222.2001.01030.x

  107. 107.

    Satpathy S. R. Jala V. R. Bodduluri S. R. Krishnan E. Hegde B. Hoyle G. W. (2015 ). Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth. Nat. Commun. 6:7064.

    Not in our library10.1038/ncomms8064

  108. 108.

    Savin J. A. (1998 ). How should we define itching? J. Am. Acad. Dermatol. 39 268–269.

    Not in our library10.1016/s0190-9622(98)70087-8

  109. 109.

    Schmetzer O. Lakin E. Topal F. A. Preusse P. Freier D. Church M. K. (2018 ). IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J. Allergy Clin. Immunol. 142 876–882.

    Not in our library10.1016/j.jaci.2017.10.035

  110. 110.

    Shim W. S. Tak M. H. Lee M. H. Kim M. Kim M. Koo J. Y. (2007 ). TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J. Neurosci. 27 2331–2337.

    Not in our library10.1523/jneurosci.4643-06.2007

  111. 111.

    Siiskonen H. Poukka M. Bykachev A. Tyynelä-Korhonen K. Sironen R. Pasonen-Seppänen S. (2015 ). Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma. Melanoma Res. 25 479–485.

    Not in our library10.1097/cmr.0000000000000192

  112. 112.

    Singh L. K. Pang X. Alexacos N. Letourneau R. Theoharides T. C. (1999 ). Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav. Immun. 13 225–239.

    Not in our library10.1006/brbi.1998.0541

  113. 113.

    Sommer F. Hensen P. Bockenholt B. Metze D. Luger T. A. Ständer S. (2007 ). Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm. Venereol. 87 510–516.

    Not in our library10.2340/00015555-0320

  114. 114.

    Sonkoly E. Muller A. Lauerma A. I. Pivarcsi A. Soto H. Kemeny L. (2006 ). IL-31: a new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 117 411–417.

    Not in our library10.1016/j.jaci.2005.10.033

  115. 115.

    Spinnler K. Frohlich T. Arnold G. J. Kunz L. Mayerhofer A. (2011 ). Human tryptase cleaves pro-nerve growth factor (pro-NGF): hints of local, mast cell-dependent regulation of NGF/pro-NGF action. J. Biol. Chem. 286 31707–31713.

    Not in our library10.1074/jbc.m111.233486

  116. 116.

    Ständer S. Moormann C. Schumacher M. Buddenkotte J. Artuc M. Shpacovitch V. (2004 ). Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp. Dermatol. 13 129–139.

    Not in our library10.1111/j.0906-6705.2004.0178.x

  117. 117.

    Ständer S. Ständer H. Seeliger S. Luger T. A. Steinhoff M. (2007a ). Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br. J. Dermatol. 156 1020–1026.

    Not in our library10.1111/j.1365-2133.2007.07813.x

  118. 118.

    Ständer S. Weisshaar E. Mettang T. Szepietowski J. C. Carstens E. Ikoma A. (2007b ). Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm. Venereol. 87 291–294.

    Not in our library10.2340/00015555-0305

  119. 119.

    Steinhoff M. Neisius U. Ikoma A. Fartasch M. Heyer G. Skov P. S. (2003 ). Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23 6176–6180.

    Not in our library10.1523/jneurosci.23-15-06176.2003

  120. 120.

    Suarez A. L. Feramisco J. D. Koo J. Steinhoff M. (2012 ). Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm. Venereol. 92 7–15.

    Not in our library10.2340/00015555-1188

  121. 121.

    Subramanian H. Gupta K. Ali H. (2016 ). Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J. Allergy Clin. Immunol. 138 700–710.

    Not in our library10.1016/j.jaci.2016.04.051

  122. 122.

    Sugimoto Y. Umakoshi K. Nojiri N. Kamei C. (1998 ). Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Eur. J. Pharmacol. 351 1–5.

    Not in our library10.1016/s0014-2999(98)00288-x

  123. 123.

    Szepietowski J. C. Reich A. (2016 ). Pruritus in psoriasis: an update. Eur. J. Pain 20 41–46.

    Not in our library10.1002/ejp.768

  124. 124.

    Talagas M. Lebonvallet N. Leschiera R. Marcorelles P. Misery L. (2018 ). What about physical contacts between epidermal keratinocytes and sensory neurons? Exp. Dermatol. 27 9–13.

    Not in our library10.1111/exd.13411

  125. 125.

    Taneda K. Tominaga M. Negi O. Tengara S. Kamo A. Ogawa H. (2011 ). Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br. J. Dermatol. 165 277–284.

    Not in our library10.1111/j.1365-2133.2011.10347.x

  126. 126.

    Taracanova A. Alevizos M. Karagkouni A. Weng Z. Norwitz E. Conti P. (2017 ). SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc. Natl. Acad. Sci. U.S.A. 114 E4002–E4009.

    Not in our library10.1073/pnas.1524845114

  127. 127.

    Taracanova A. Tsilioni I. Conti P. Norwitz E. R. Leeman S. E. Theoharides T. C. (2018 ). Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. Proc. Natl. Acad. Sci. U.S.A. 115 E9381–E9390.

    Not in our library10.1073/pnas.1810133115

  128. 128.

    Terakawa M. Fujieda Y. Tomimori Y. Muto T. Tanaka T. Maruoka H. (2008 ). Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur. J. Pharmacol. 601 186–191.

    Not in our library10.1016/j.ejphar.2008.10.040

  129. 129.

    Tettamanti L. Kritas S. K. Gallenga C. E. D’Ovidio C. Mastrangelo F. Ronconi G. (2018 ). IL-33 mediates allergy through mast cell activation: potential inhibitory effect of certain cytokines. J. Biol. Regul. Homeost. Agents 32 1061–1065.

    Not in our library

  130. 130.

    Theoharides T. C. Donelan J. Kandere-Grzybowska K. Konstantinidou A. (2005 ). The role of mast cells in migraine pathophysiology. Brain Res. Brain Res. Rev. 49 65–76.

    Not in our library10.1016/j.brainresrev.2004.11.006

  131. 131.

    Theoharides T. C. Kavalioti M. (2018 ). Stress, inflammation and natural treatments. J. Biol. Regul. Homeost. Agents 32 1345–1347.

    Not in our library

  132. 132.

    Tobin D. Nabarro G. Baart de la Faille H. van Vloten W. A. van der Putte S. C. Schuurman H. J. (1992 ). Increased number of immunoreactive nerve fibers in atopic dermatitis. J. Allergy Clin. Immunol. 90 613–622.

    Not in our library10.1097/01206501-199306000-00026

  133. 133.

    Tomimori Y. Muto T. Fukami H. Saito K. Horikawa C. Tsuruoka N. (2002 ). Mast cell chymase regulates dermal mast cell number in mice. Biochem. Biophys. Res. Commun. 290 1478–1482.

    Not in our library10.1006/bbrc.2002.6365

  134. 134.

    Tominaga M. Takamori K. (2014 ). Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J. Dermatol. 41 205–212.

    Not in our library10.1111/1346-8138.12317

  135. 135.

    Tominaga M. Tengara S. Kamo A. Ogawa H. Takamori K. (2009 ). Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J. Dermatol. Sci. 55 40–46.

    Not in our library10.1016/j.jdermsci.2009.03.007

  136. 136.

    Toth-Jakatics R. Jimi S. Takebayashi S. Kawamoto N. (2000 ). Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum. Pathol. 31 955–960.

    Not in our library10.1053/hupa.2000.16658

  137. 137.

    Tunon de Lara J. M. Okayama Y. McEuen A. R. Heusser C. H. Church M. K. Walls A. F. (1994 ). Release and inactivation of interleukin-4 by mast cells. Ann. N. Y. Acad. Sci. 725 50–58.

    Not in our library10.1111/j.1749-6632.1994.tb39789.x

  138. 138.

    Ui H. Andoh T. Lee J. B. Nojima H. Kuraishi Y. (2006 ). Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur. J. Pharmacol. 530 172–178.

    Not in our library10.1016/j.ejphar.2005.11.021

  139. 139.

    Urashima R. Mihara M. (1998 ). Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. Virchows Arch. 432 363–370.

    Not in our library10.1007/s004280050179

  140. 140.

    van der Zee H. H. de Ruiter L. Boer J. van den Broecke D. G. den Hollander J. C. Laman J. D. (2012 ). Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br. J. Dermatol. 166 98–106.

    Not in our library10.1111/j.1365-2133.2011.10643.x

  141. 141.

    Walls A. F. Brain S. D. Desai A. Jose P. J. Hawkings E. Church M. K. (1992 ). Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene-related peptide. Biochem. Pharmacol. 43 1243–1248.

    Not in our library10.1016/0006-2952(92)90498-8

  142. 142.

    Watanabe N. Tomimori Y. Terakawa M. Ishiwata K. Wada A. Muto T. (2007 ). Oral administration of chymase inhibitor improves dermatitis in NC/Nga mice. J. Invest. Dermatol. 127 971–973.

    Not in our library10.1038/sj.jid.5700708

  143. 143.

    Weber A. Knop J. Maurer M. (2003 ). Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br. J. Dermatol. 148 224–228.

    Not in our library10.1046/j.1365-2133.2003.05090.x

  144. 144.

    Weidner C. Klede M. Rukwied R. Lischetzki G. Neisius U. Skov P. S. (2000 ). Acute effects of substance P and calcitonin gene-related peptide in human skin–a microdialysis study. J. Invest. Dermatol. 115 1015–1020.

    Not in our library10.1046/j.1523-1747.2000.00142.x

  145. 145.

    Xiang Z. Nilsson G. (2000 ). IgE receptor-mediated release of nerve growth factor by mast cells. Clin. Exp. Allergy 30 1379–1386.

    Not in our library10.1046/j.1365-2222.2000.00906.x

  146. 146.

    Yamaguchi J. Nakamura F. Aihara M. Yamashita N. Usui H. Hida T. (2008 ). Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J. Invest. Dermatol. 128 2842–2849.

    Not in our library10.1038/jid.2008.150

  147. 147.

    Yamaoka J. Kawana S. (2007 ). Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J. Dermatol. Sci. 48 123–132.

    Not in our library10.1016/j.jdermsci.2007.06.007

  148. 148.

    Yamaura K. Oda M. Suwa E. Suzuki M. Sato H. Ueno K. (2009 ). Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J. Toxicol. Sci. 34 427–431.

    Not in our library10.2131/jts.34.427

  149. 149.

    Yosipovitch G. Mills K. C. Nattkemper L. A. Feneran A. Tey H. L. Lowenthal B. M. (2014 ). Association of pain and itch with depth of invasion and inflammatory cell constitution in skin cancer: results of a large clinicopathologic study. JAMA Dermatol. 150 1160–1166.

    Not in our library10.1001/jamadermatol.2014.895

  150. 150.

    Zhao W. Oskeritzian C. A. Pozez A. L. Schwartz L. B. (2005 ). Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines. J. Immunol. 175 2635–2642.

    Not in our library10.4049/jimmunol.175.4.2635

  151. 151.

    Zhu Y. Pan W. H. Wang X. R. Liu Y. Chen M. Xu X. G. (2015 ). Tryptase and protease-activated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. Int. Immunopharmacol. 28 507–512.

    Not in our library10.1016/j.intimp.2015.04.047

  152. 152.

    Zhu Y. Wang X. R. Peng C. Xu J. G. Liu Y. X. Wu L. (2009 ). Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. Int. Immunopharmacol. 9 1332–1336.

    Not in our library10.1016/j.intimp.2009.08.006

  153. 153.

    Zuberbier T. Aberer W. Asero R. Abdul Latiff A. H. Baker D. Ballmer-Weber B. (2018 ). The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73 1393–1414.

    Not in our library10.1111/all.13397

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.